Outlook Therapeutics® to Present at the SVB Securities Global Biopharma Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Outlook Therapeutics Highlights Presentation at SVB Securities Global Biopharma Conference
On February 14, 2023, at 4:20 PM ET, Russ Trenary, President and CEO of Outlook Therapeutics (Nasdaq: OTLK), will present at the SVB Securities Global Biopharma Conference. The company aims to develop the first FDA-approved ophthalmic formulation of bevacizumab (ONS-5010) for retinal diseases. The FDA accepted its BLA submission for ONS-5010 with a PDUFA goal date of August 29, 2023. Outlook is also partnering with AmerisourceBergen for strategic commercialization to enhance distribution and patient connection ahead of potential approval.
Details
News Market Reaction – OTLK
The recorded move for OTLK in the trading session of this news was +0.79%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
– Russ Trenary, President and Chief Executive Officer of Outlook Therapeutics to present on Tuesday, February 14th at 4:20 PM ET –
ISELIN, N.J., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that Russ Trenary, President and Chief Executive Officer of Outlook Therapeutics, will present at the SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 4:20 PM ET.
In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
A live video webcast of the presentation will be accessible on the Events page in the Investors section of the Company’s website (outlooktherapeutics.com). The webcast replay will be archived for 90 days following the event.
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a biopharmaceutical company working to develop and launch ONS-5010/ LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO. The FDA accepted Outlook Therapeutics’ BLA submission for ONS-5010 to treat wet AMD with a PDUFA goal date of August 29, 2023. The submission is supported by Outlook Therapeutics’ wet AMD clinical program, which consists of three clinical trials: NORSE ONE, NORSE TWO, and NORSE THREE. If ONS-5010 ophthalmic bevacizumab is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan, and other markets. As part of the Company’s multi-year commercial planning process, and in anticipation of potential FDA approval in August 2023, Outlook Therapeutics and AmerisourceBergen have entered into a strategic commercialization agreement to expand the Company’s reach for connecting to retina specialists and their patients. AmerisourceBergen will provide third-party logistics (3PL) services and distribution, as well as pharmacovigilance services in the United States. For more information, please visit www.outlooktherapeutics.com.
CONTACTS:
Media Inquiries:
Harriet Ullman
Vice President
LaVoie Health Science
T: 617-669-3082
hullman@lavoiehealthscience.com
Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 833.475.8247
OTLK@jtcir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.